Excellent question!!: I only know of 2 small studies (netherlands and us) in which mammaprint was evaluated in a pre-op setting. A "high risk" category was predictive of a pathologic complete response (desirable). I believe there is at least one ongoing trial (mint i) and maybe more studying that question. For now, microarray tests are used in the post-op setting for er+, node negative patients in routine practice.
Answered 12/10/2013
5.1k views
7 doctors weighed in across 4 answers
A doctor has provided 1 answer
4 doctors weighed in across 2 answers
A doctor has provided 1 answer
3 doctors weighed in across 3 answers
90,000 U.S. doctors in 147 specialties are here to answer your questions or offer you advice, prescriptions, and more.
Ask your question